Metformin Cessation and Dementia Incidence

Area of Science:

• Gerontology
• Neurology
• Pharmacology

Background:

• Previous studies indicated metformin might reduce dementia incidence.
• However, these associations could be confounded by diabetes severity and prescribing patterns.
• Metformin cessation often occurs due to kidney dysfunction but also for other adverse effects.

Purpose of the Study:

• To investigate the link between stopping metformin for non-kidney-related reasons and dementia incidence.
• To explore the potential neuroprotective effects of metformin in diabetes management.

Main Methods:

• A cohort study at Kaiser Permanente Northern California included metformin users without prior kidney disease.
• 12,220 early terminators (stopped metformin with normal kidney function) were compared to routine users.
• Survival and mediation models analyzed dementia incidence, adjusting for confounders and assessing the role of glycemic control.

Main Results:

• Early metformin termination was associated with a 21% increased hazard of dementia diagnosis (HR, 1.21; 95% CI, 1.12-1.30).
• This association appeared largely independent of changes in HbA1c levels or insulin usage post-termination.
• Mediation analysis indicated minimal contribution from glycemic control changes to the observed association.

Conclusions:

• Discontinuing metformin for reasons other than kidney dysfunction is linked to higher dementia incidence.
• These findings support the hypothesis that metformin may have a protective effect against dementia.
• Implications for clinical practice regarding metformin use in diabetes management and dementia prevention.